Douglas Jeffery

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

Peter A. Calabresi, Ernst-Wilhelm Radüe, Douglas S. Goodin et al. · The Lancet Neurology · 2014 · 822 citations

Pharmacy, Neurology, Pharmacotherapy +7

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

Daniel D. Mikol, Frederik Barkhof, Peter Chang et al. · The Lancet Neurology · 2008 · 484 citations

Life Sciences, Neurology, Pharmacotherapy +13

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

Paul O’Connor, Massimo Filippi, Barry G.W. Arnason et al. · The Lancet Neurology · 2009 · 403 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +8

Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis

Douglas Jeffery, Ludwig Kappos, Xavier Montalbán et al. · New England Journal of Medicine · 2012 · 362 citations · Full text

Medicine, Neurology, Pharmacotherapy +7

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 337 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14